Literature DB >> 2322201

Complications and causes of death in B cell chronic lymphocytic leukaemia: a long term study of 105 patients.

T I Robertson1.   

Abstract

The complications and causes of death of 105 patients with B cell chronic lymphocytic leukaemia followed for a median period of 5.5 years are described. Infection and secondary primary malignant tumours were the most common complications and also caused most deaths. S. pneumoniae, S. aureus, S. haemolyticus, E. coli and the zoster-varicella virus accounted for most infections and the lungs, skin and urinary tract were the sites affected. Even trivial infections were potentially serious. Haemolytic anaemia and vascular complications were also common. Older patients tended to have a shorter survival than the mean for the group whereas younger patients fared better. The mean survival was 6.2 years. Analysis confirmed the prognostic value of Rai staging. Advancing disease increased the liability to major infection. Light bone marrow infiltration five years post diagnosis indicated a good prognosis and preservation of normal immunoglobulin levels seemed beneficial. Immunoglobulin deficiency is the factor that correlates best with the frequency, severity and pattern of infection. Early stage disease provides a distinct benefit and there may be advantages in prompt diagnosis, regular assessment by immunoglobulin levels and bone marrow pattern and treatment on the first evidence of advancing disease. Fresh symptoms should be investigated in their own right because of the likelihood of second tumours.

Entities:  

Mesh:

Year:  1990        PMID: 2322201     DOI: 10.1111/j.1445-5994.1990.tb00370.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  4 in total

1.  Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.

Authors:  Markus Jensen; Andreas Engert; Florian Weissinger; Wolfgang Knauf; Eva Kimby; Christopher Poynton; Ira Anton Oliff; Mathias J Rummel; Anders Osterborg
Journal:  Invest New Drugs       Date:  2007-12-20       Impact factor: 3.850

2.  Chronic lymphocytic leukaemia at a county hospital in southern Sweden.

Authors:  V Hjalmar; M Carlsson; E Kimby
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

3.  Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia.

Authors:  Doru T Alexandrescu; Peter H Wiernik
Journal:  Med Oncol       Date:  2008-01-05       Impact factor: 3.064

4.  The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.

Authors:  Hila Shaim; Zeev Estrov; David Harris; Mayra Hernandez Sanabria; Zhiming Liu; Peter Ruvolo; Phillip A Thompson; Alessandra Ferrajoli; May Daher; Jan Burger; Muharrem Muftuoglu; Nobuhiko Imahashi; Li Li; Enli Liu; Abdullah Saleh Alsuliman; Rafet Basar; Lucila Nassif Kerbauy; Catherine Sobieski; Elif Gokdemir; Kayo Kondo; William Wierda; Michael Keating; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Front Immunol       Date:  2018-01-15       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.